A5069106726- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Cytokine Signaling Pathways and Interactions
- Pharmacological Effects of Natural Compounds
- Monoclonal and Polyclonal Antibodies Research
- Peripheral Neuropathies and Disorders
- Toxin Mechanisms and Immunotoxins
- Psoriasis: Treatment and Pathogenesis
- Gout, Hyperuricemia, Uric Acid
- Urticaria and Related Conditions
- IL-33, ST2, and ILC Pathways
- Healthcare cost, quality, practices
- Microscopic Colitis
- Proteoglycans and glycosaminoglycans research
- Adolescent and Pediatric Healthcare
- Blood transfusion and management
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Long-Term Effects of COVID-19
- Viral Infections and Immunology Research
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Clinical Laboratory Practices and Quality Control
- Tuberculosis Research and Epidemiology
Yaroslavl State Medical Academy
2016-2025
Clinical Hospital No. 8
2024
Ministry of Health of the Russian Federation
2020-2024
VA Nasonova Scientific Research Institute of Rheumatology
2016
Relevance. The determination of reference intervals (RI) in clinical blood analysis for erythrocytes and their specific parameters: mean corpuscular volume (MCV), hemoglobin (MCH), concentration (MCHC), red cell distribution width (RDW), allows us to use these parameters differential diagnostics various pathological conditions from variants norm. Objective. Calculate the RI erythrocyte a complete count patients certain age group (18– 45 years) with normal indicators iron homeostasis. ranges...
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease of unknown etiology that represents a considerable burden for both the patient and healthcare system. The degree to which inflammation being controlled determines prognosis; therefore, achieving remission or low activity paramount importance medical practitioners. effectiveness currently employed treatment regimen specific determined by indices change in their values during treatment. commonly used RA are result painstaking...
Oral treatment of glucosamine (GA) combined with chondroitin sulfate (CS) was reportedly effective for pain relief and function improvement in osteoarthritis patients moderate to severe knee clinical trials. While the effectiveness GA CS on both radiological findings has been demonstrated, only a few high-quality trials exist. Therefore, controversy regarding their real-world practice remains.To investigate impact + outcomes hip routine practice.A multicenter prospective observational cohort...
Aim . Switching to another biologic with the same mode of action provides greater opportunity for long-term management patients rheumatoid arthritis (RA). In clinical practice, especially in context COVID-19 pandemic, such switching occurred non-medical reasons as well. However, there is no information about from interleukin 6 (IL-6) receptor (R) inhibitor direct IL-6 inhibitor. Objective – assess efficacy and safety therapy RA patients, after IL-6R inhibitors (tocilizumab (TOC), sarilumab...
Objective : to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons. Material methods . A retrospective cohort study conducted 11 centers Russian Federation included 110 confirmed diagnosis RA according 2010 ACR/EULAR criteria. In all early 2022 (due problems drug supply during coronavirus pandemic) iIL6R were switched reasons OKZ at...
The aim of the study was to determine clinical and diagnostic value interleukin (IL) 17A, IL-17F IL-23 in rheumatoid arthritis (RA) patients advanced stage disease. Materials methods. We examined 154 with a reliable diagnosis RA according ACR/EULAR (American College Rheumatology/European Alliance Associations for Rheumatology) criteria (2010), predominantly (73.4%) female, middle-aged (56.0 (50.0; 64.0) years), disease duration 9.4 (3.0; 13.0) years, radiologic stages II (34.4%) III (37.0%),...
Abstract Aim Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) real‐world clinical practice, a targeted assessment of patient report outcomes (PRO) central sensitization. Methods An open‐label observational non‐interventional study was conducted, enrolling 183 moderate severe RA activity. All received OKZ 64 mg SC as injections every 4 weeks (Q4W) methotrexate. The patients' follow‐up period 24 or less. activity (DAS28‐CRP), pain severity (NRS),...
Objective: to analyze the results of tofacitinib (TOFA) therapy in real clinical practice according All-Russian Arthritis Registry (OREL). Subjects and methods. The OREL included 347 patients (286 (82%) women 61 (18%) men) with rheumatoid arthritis (RA) who initiated TOFA therapy. male:female ratio was 1:4.7. patients’ median age at onset disease 42 years; its duration 8 years. Most registry had extended- (n=171 (52%)) or late- (n=148 (45%)) stage RA. Results discussion. Prior initiation...
The aim of the study was to investigate dynamics clinical and laboratory parameters inflammatory disease activity cytokines in patients with rheumatoid arthritis (RA) against background olokizumab (OKZ) treatment. Materials methods. Ten a reliable diagnosis RA were examined: patients’ age 46.00 (30.00; 60.00) years, duration 9.0 (3.0; 12,0) years. All had moderate high activity: DAS28-ESR (Disease Activity Score 28 Erythrocyte Sedimentation Rate) – 513 (4.34; 5,80); CDAI (Clinical Disease...
Abstract The aim of the study was to evaluate effectiveness UPA in RA patients real clinical practice after 3 and 6 months therapy. included 63 with high activity disease. Activity assessed according DAS28(ESR), DAS28(CRP), SDAI, CDAI; functional ability HAQ; quality life EQ-5D; disease patient’s RAPID-3 index; level depression anxiety HADS scale. therapy evaluated ( n = 45) 31) Remission or low by achieved most patients: remission 69.8% patients, disease—16.3% patients. Moderate persisted...
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates synthesis of cytokines and mediators involved in development pain central sensitization (CS), which determines rapid analgesic effect. However, it is not clear how reduction associated with achieving low activity rheumatoid arthritis (RA). aim study was to assess relationship between early clinical response a decrease after 3 6 months. Material methods. group consisted 88 RA patients (age – 53±11.5...
Objective - to study the dynamics of clinical and laboratory parameters inflammatory activity disease cytokines in rheumatoid arthritis (RA) patients on a background tofacitinib (TOFA) treatment. Material methods . Ten with reliable diagnosis RA have been examined: patients' age was 51.0 (48.0; 62.0) years, duration 7.0 (3.0; 20.0) years. All had high activity: DAS28 -5.88 (5.53; 5.94), CDAI 33.0 (29.0; 36.0), SDAI 33.72 (30.75; 36.85). were treated TOFA at dose 5 mg 2 times day methotrexate...
The aim of the study was to evaluate effectiveness UPA in RA patients real clinical practice after 3 and 6 months therapy. Material methods . included 63 with high activity disease. Activity assessed according DAS28 (ESR), (CR P), SDAI, CDAI; functional ability HAQ; quality life EQ-5D; disease patient’s RAPID-3 index; level depression anxiety HADS scale. therapy evaluated (n=45) (n=31) Results Remission or low by achieved most patients: remission 69.8% patients, – 16.3% patients. Moderate...
Aim: to perform an indirect comparative analysis of changes over time in clinical and laboratory parameters inflammatory activity rheumatoid arthritis (RA) patients who receive tofacitinib (TOFA), upadacitinib (UPA), olokizumab (OKZ) real practice. Patients Methods: the study included 30 with advanced RA moderate or high (DAS28-ESR score) had ineffective prior therapy methotrexate, leflunomide, genetically engineered biological drugs for at least 6 months. The were divided into three groups:...
Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role the pathogenesis RA. JAK inhibitors bDMARD are aimed at suppressing various pathological reactions caused by them. The aim study . To determine effect therapy with IL-6 on concentration RA patients real clinical practice. Materials methods. included 30 a reliable diagnosis RA, advanced stage disease, moderate or high activity ineffectiveness previous csDMARD for least 6 months. 10 received...
Relevance. Activation of innate and acquired immunity, accompanied by increased production classical (interleukin (IL) IL-1β, IL-6, tumor necrosis factor-α (TNF-α) interferon-γ (INF-γ)) proinflammatory cytokines in synovial fluid blood serum, plays an important role the pathogenesis rheumatoid arthritis (RA). Objective. To determine concentration TNF-α INF-γ RA patients advanced stage disease, to evaluate relationship between them, clinical indices disease activity, presence factor (RF),...
In the pathogenesis of rheumatoid arthritis (RA), an important role is played by dysfunction between production main anti-inflammatory interleukins (IL) IL-4, IL-10 and proinflammatory (IL-6) cytokines. Objective. Determination IL-6 concentrations in RA patients with advanced stage disease, assessment relationship them, clinical indices disease activity, presence factor (RF) antibodies to cyclic citrullinated peptide (CCP). Material methods. The study included 154 (41 males 113 females)...
This article describes the experience of using type I interferon inhibitor anifrolumab (AFM) in a patient with torpid course systemic lupus erythematosus. The reason for prescribing AFM was need quick achievement low disease activity due to planned hip replacement. Dynamic observational data over six-month period confirmed that enables rapid without increasing dose glucocorticoids, significantly improve patient's quality life and even prepare them major surgery exacerbating underlying process.
Imbalance in the production of pro- and anti-inflammatory cytokines plays an important role pathogenesis rheumatoid arthritis (RA). The aim study. To determine concentration frequency increase serum patients with RA advanced stage disease, assessment relationship between them, clinical laboratory activity disease autoantibodies. Materials methods. We examined 154 (41 men 113) women, average age (56.0 [50.0; 64.0] years), duration (9.4 [3.0; 13.0] seropositive 129 (83.8 %) for IgM factor (RF)...
<h3>Background</h3> Russian register of patients with inflammatory arthritis started in 2012 as a RA ("All-Russian Rheumatoid Artritis"- ARRA) now transformed into "Observational REgister cLinical practice" (OREL), including rheumatoid (RA), psoriatic and adults juvenile arthritis. <h3>Objectives</h3> To study reasons for withdrawal biological DMARDs clinical practice Russia. <h3>Methods</h3> Data 1398 pts (286 men, 1112 women, medium age 50,5 years), treated DMARDs, were included OREL...
Upadacitinib (UPA), a JAK inhibitor, is new therapeutic option that allows patients with insufficient response to therapy basic anti-inflammatory drugs (DMARDs) or genetically engineered biological (GEBDs) achieve the goals of for rheumatoid arthritis (RA). Despite availability convincing data from international randomized clinical trials, there information about efficacy and safety profile UPA, quality life receiving drug in real practice. Aim study – assess tolerability UPA at dose 15...
<h3>Background:</h3> In previous studies tofacitinib (TF) had demonstrated efficacy of two dosages (10 and 20 mg/day) in patients with rheumatoid arthritis (RA). However, the expected results switching TF' are unknown. <h3>Objectives:</h3> <b>The aim</b> study was to evaluate TF's RA patients. <h3>Methods:</h3> Were analyzed data from Russian national register treated TF (tofacitinib). 415 were involved (aug 2018). statistical analysis included 41 (EULAR 2010), who switched dosage at visit 3...
Objective – to investigate clinical and diagnostic significance of IL-31 IL-33 determination in patients with rheumatoid arthritis (RA). Material methods. 154 a reliable diagnosis RA were examined. Serum levels studied using multiplex xMAP technology on Bio-PlexTM 200 System analyzer (BIO-RAD, USA). The upper limit the norm study 20 healthy donor sera was (M+3σ): 15.08 pg/ml, 3.40 pg/ml. Results. (Me (25th; 75th percentile) 13.75 (5.63; 308.52) 6.10 (2.87; 8.62) pg/ml (p<0.001), 18.86...